Variations to introduction scenario | Â | Â | Â | Â | Â | Â | ||
---|---|---|---|---|---|---|---|---|
 | Reduction in condom use | Coverage | Consistency of gel use | HIV efficacy | $/DALY averted | % change | Threshold price | % change |
Baseline | 0% | 30% | 72% | 54% | $297 | Â | $0.12 | Â |
 | 5% | 30% | 72% | 54% | $586 | 97% | $0.03 | -74% |
 | 10% | 30% | 72% | 54% | $1,219 | 310% | cannot be achieved |  |
 | 0% | 60% | 72% | 54% | $285 | -4% | $0.13 | 5% |
 | 0% | 60% | 50% | 54% | $468 | 58% | $0.03 | -78% |
 | 0% | 30% | 72% | 83% | -$14 | -105% | $0.33 | 166% |
Cost sensitivity analysis | Â | Â | Â | Â | Â | Â | Â | |
1 dose per sex-act | Â | Â | Â | $78 | -74% | $0.25 | 100% | |
Discount rate 0% | Â | Â | Â | Â | -$243 | -182% | $0.43 | 244% |
Discount rate 6% | Â | Â | Â | Â | $525 | 77% | cannot be achieved | Â |
ART costs 10% lower | Â | Â | Â | $344 | 16% | $0.10 | -21% | |
ART costs 25% lower | Â | Â | Â | $413 | 39% | $0.06 | -53% | |
All other input costs 25% higher | Â | Â | Â | $402 | 35% | $0.06 | -48% | |
All other input costs 25% lower | Â | Â | Â | $193 | -35% | $0.18 | 48% | |
Input +25%, ART-10% | Â | Â | Â | $448 | 51% | $0.04 | -69% | |
Input +25%, ART-25% | Â | Â | Â | $518 | 74% | -$0.00 | -100% | |
ART coverage 80% | Â | Â | Â | $163 | -45% | $0.24 | 90% |